Extensive evidence has indicated that the breakdown of myelin is associated with
Alzheimer's disease (AD) since the vulnerability of oligodendrocytes under Alzheimer's …

Postoperative cognitive dysfunction (POCD) has been reported with widely varying
frequency but appears to be strongly associated with aging. Outside of the surgical arena …

In view of the rapid preclinical development of cell-based therapies for neurodegenerative
disorders, traumatic brain injury, and tumors, the safe and efficient delivery and targeting of …

A significant portion of the world's population suffers from sporadic Alzheimer's disease (AD)
with available present therapies limited to symptomatic care that does not alter disease …

Erythropoietin (EPO), a glycoprotein cytokine essential to hematopoiesis, has
neuroprotective effects in rodent models of Alzheimer's disease (AD). However, high …

Globally, greater than 30 million individuals are afflicted with disorders of the nervous
system accompanied by tens of thousands of new cases annually with limited, if any …

Angiotensin receptor blockers (ARBs) have demonstrated multiple neuroprotective benefits
in Alzheimer's disease (AD) models. However, their beneficial effects on memory deficits …

Erythropoietin (Epo) is a fundamental hormone in the regulation of hematopoiesis, and other
secondary roles mediated by the binding of the hormone to its specific receptor (EpoR) …

Abstract Erythropoietin (EPO) is a 30.4 kDa growth factor and cytokine that governs cell
proliferation, immune modulation, metabolic homeostasis, vascular function, and …

Life expectancy continues to increase throughout the world, but is accompanied by a rise in
the incidence of non-communicable diseases. As a result, the benefits of an increased …